Rationale & ObjectivePostpartum renal cortical necrosis (postpartum RCN) is a severe form of obstetric acute kidney injury. This study aimed to identify clinicopathological features in Chinese postpartum RCN cases to determine how pathologic findings may contribute to the treatment and prognosis. Study DesignSingle-center, case series Setting & ParticipantsTwelve patients with postpartum RCN had kidney biopsies at Peking University First Hospital between 2014 and 2021. The diagnosis of postpartum RCN was made according to typical MRI or pathological features. Clinical, laboratory and pathological data were compared between patients with eGFR <30 (poor outcome) and ≥30 ml/min/1.73 m2 after six months. ObservationsAll postpartum RCN patients presented with stage 3 AKI attributed to a probable atypical hemolytic uremic syndrome. Pregnancy terminations occurred at a median gestational age of 35.5 weeks. Kidney biopsy was performed ranging 18 days to 4 months from delivery. Upon biopsy, hemoglobin, platelet count and LDH levels had been restored to 137 g/L, 214 ×109/L and 231.50±65.01 U/L, respectively. Four patients exhibited poor outcome, demonstrating higher schistocyte count, serum creatinine and mean arterial pressure at onset. Pathologically, glomerular segmental sclerosis was prevalent. The NOS variant was the most common type, followed by collapsing variant, cellular variant, and tip variant. Patients with poor kidney outcome had more glomerular coagulative necrosis, capillary thrombosis, extensive cortical coagulative necrosis, and pronounced arteriole/artery lesions including increased interlobular arteriole intimal edema and fibrin thrombosis, but a lower occurrence of segmental sclerosis. LimitationsLimited sample size and retrospective design. ConclusionsOur research has identified key pathological features in postpartum RCN patients with aHUS, highlighting the necessity for more effective therapeutic options. There is a clear demand for non-invasive biomarkers that can accurately track disease progression and inform treatment duration for long-term outcomes improvement.